Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

CD22 expression occurs in >90% of patients with acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, is active in ALL.

[1]  H. Kantarjian,et al.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.

[2]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Hoelzer,et al.  Modern therapy of acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Deng,et al.  Chemoimmunotherapy with A Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia , 2011 .

[5]  J. Byrd,et al.  Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002 , 2010 .

[6]  T. Lipp,et al.  Immunochemotherapy with Rituximab Improves Molecular CR Rate and Outcome In CD20+ B-Lineage Standard and High Risk Patients; Results of 263 CD20+ Patients Studied Prospectively In GMALL Study 07/2003 , 2010 .

[7]  C. Pui,et al.  Adult acute lymphoblastic leukemia , 2010, Cancer.

[8]  H. Kantarjian,et al.  Outcome of adults with acute lymphocytic leukemia after second salvage therapy , 2008, Cancer.

[9]  M. Borowitz,et al.  Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Franchini.  Rituximab in the treatment of adult acquired hemophilia A: a systematic review. , 2007, Critical reviews in oncology/hematology.

[11]  H. Kantarjian,et al.  Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.

[12]  H. Kantarjian,et al.  Adult acute lymphoblastic leukemia. , 2005, Mayo Clinic proceedings.

[13]  T. Lipp,et al.  Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). , 2000, Hematology/oncology clinics of North America.

[14]  J. Thorson,et al.  Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. , 2000, Current pharmaceutical design.

[15]  Terry L. Smith,et al.  Primary refractory and relapsed adult acute lymphoblastic leukemia , 1999, Cancer.